Ibogaine for the treatment of Parkinson's disease: A case report
Journal of Psychedelic Studies January 6, 2026 Tobias Erny, Elba Yatziri Cano Montenegro, Joern Barth et al.
A 52-year-old woman with Parkinson's disease who was becoming less responsive to standard treatment took daily low doses of ibogaine hydrochloride (up to 75 mg) for 80 days. After treatment, she showed substantial improvements in motor symptoms, quality of life, fatigue, and depression, as measured by validated clinical scales. However, her sleep quality declined, possibly due to ibogaine's stimulant effects. She also reported fewer freezing episodes, better mobility, more energy, and greater optimism. No adverse events occurred. This first case study using validated instruments suggests ibogaine may alleviate Parkinson's symptoms, but larger controlled trials are needed.